Arrhythmias & EP
From the Journals
OSA raises risk of atrial fibrillation and stroke
Silent atrial fibrillation was common in patients with moderate to severe obstructive sleep apnea, compared with controls.
Conference Coverage
First-line AFib ablation cuts risk of progression vs. drug therapy
Atrial fibrillation treated with ablation rather than drug therapy was less likely to progress to persistent symptoms in the PROGRESSIVE-AF trial...
Conference Coverage
AHA 2022 to recapture in-person vibe but preserve global reach
Planners see the meeting’s Chicago return as a hybrid after 2 years relegated to cyberspace as a chance for first impressions on some just...
From the Journals
Best anticoagulant for minimizing bleeding risk identified
“Apixaban stood out as having lower risk of gastrointestinal bleeding.”
From the Journals
IV potassium and magnesium an acute treatment for AFib?
“It’s simple, inexpensive, you make the heart rate go back to normal, not permanently, with few side effects, except perhaps for some pain at the...
From the Journals
Four commonly abused drugs linked with atrial fibrillation
All four drugs – cocaine, methamphetamine, opioids, and cannabis – whether stimulants or depressants – cause “quite dramatic and often rapid...
News
FDA OKs Medtronic lead for left bundle branch pacing
A lead already approved for stimulating the His bundle is now also indicated for LBB pacing, another prominent form of conduction system pacing....
From the Journals
Diabetes becoming less potent risk factor for CVD events
Diabetes is no longer equal to cardiovascular disease as a risk factor for cardiovascular events, according to a population-based study in Ontario...
Feature
Apixaban outmatches rivaroxaban in patients with AFib and valvular heart disease
Compared with rivaroxaban, patients who received apixaban had a 43% reduced risk of stroke or embolism.
From the Journals
AFib detection by smartwatch challenging in some patients
Coexisting ECG anomalies may affect the accuracy of the watch’s detection algorithms.
From the Journals
New deep dive into Paxlovid interactions with CVD meds
The review tackles potential drug-drug interactions with the antiviral drug and today’s most commonly prescribed cardiovascular drugs.